Immune checkpoint molecules (PD-L1, CTLA-4, and PD1) inhibit the activity of T cells in the tumor microenvironment, thereby suppressing anti-tumor immunity-associated processes (40, 41). This evidence concerns the gene CTLA4 and neoplasm.